Literature DB >> 34216039

Curing Multiple Sclerosis: How to Know When We're There.

Stephen L Hauser1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34216039      PMCID： PMC8896903          DOI： 10.1002/ana.26155

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   11.274


× No keyword cloud information.
  29 in total

1.  Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis.

Authors:  Birgit Obermeier; Reinhard Mentele; Joachim Malotka; Josef Kellermann; Tania Kümpfel; Hartmut Wekerle; Friedrich Lottspeich; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Nat Med       Date:  2008-05-18       Impact factor: 53.440

2.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

3.  Spinal cord gray matter atrophy correlates with multiple sclerosis disability.

Authors:  Regina Schlaeger; Nico Papinutto; Valentina Panara; Carolyn Bevan; Iryna V Lobach; Monica Bucci; Eduardo Caverzasi; Jeffrey M Gelfand; Ari J Green; Kesshi M Jordan; William A Stern; H-Christian von Büdingen; Emmanuelle Waubant; Alyssa H Zhu; Douglas S Goodin; Bruce A C Cree; Stephen L Hauser; Roland G Henry
Journal:  Ann Neurol       Date:  2014-08-21       Impact factor: 10.422

4.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

5.  Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains.

Authors:  D H Mattson; R P Roos; B G Arnason
Journal:  Nature       Date:  1980-09-25       Impact factor: 49.962

6.  Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study.

Authors:  R Mancuso; D Franciotta; M Rovaris; D Caputo; A Sala; A Hernis; S Agostini; Mg Calvo; M Clerici
Journal:  Mult Scler       Date:  2014-06-16       Impact factor: 6.312

7.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

Authors:  Roberta Magliozzi; Owain Howell; Abhilash Vora; Barbara Serafini; Richard Nicholas; Maria Puopolo; Richard Reynolds; Francesca Aloisi
Journal:  Brain       Date:  2007-04       Impact factor: 13.501

8.  Silent progression in disease activity-free relapsing multiple sclerosis.

Authors:  Bruce A C Cree; Jill A Hollenbach; Riley Bove; Gina Kirkish; Simone Sacco; Eduardo Caverzasi; Antje Bischof; Tristan Gundel; Alyssa H Zhu; Nico Papinutto; William A Stern; Carolyn Bevan; Andrew Romeo; Douglas S Goodin; Jeffrey M Gelfand; Jennifer Graves; Ari J Green; Michael R Wilson; Scott S Zamvil; Chao Zhao; Refujia Gomez; Nicholas R Ragan; Gillian Q Rush; Patrick Barba; Adam Santaniello; Sergio E Baranzini; Jorge R Oksenberg; Roland G Henry; Stephen L Hauser
Journal:  Ann Neurol       Date:  2019-03-30       Impact factor: 10.422

9.  Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.

Authors:  Ludwig Kappos; Jerry S Wolinsky; Gavin Giovannoni; Douglas L Arnold; Qing Wang; Corrado Bernasconi; Fabian Model; Harold Koendgen; Marianna Manfrini; Shibeshih Belachew; Stephen L Hauser
Journal:  JAMA Neurol       Date:  2020-09-01       Impact factor: 18.302

Review 10.  Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.

Authors:  Hans Lassmann
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561
View more
  1 in total

1.  Epstein-Barr virus sparks brain autoimmunity in multiple sclerosis.

Authors:  Hartmut Wekerle
Journal:  Nature       Date:  2022-03       Impact factor: 49.962
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.